Travel burden slows clinical trial enrollment and drives dropout. In CISCRP's 2025 survey of 4,415 study participants, having to travel to the study clinic was the top source of disruption, named by 49% of those who found participation disruptive. Among participants who left a study early, 13% cited the study center's location. In a 2022 ASCO study of 421 early-phase oncology trial patients, 51.5% traveled 50 or more miles one way, and patients from more socially deprived areas were less likely to travel that far. More than a third of participants in CISCRP's 2025 survey (37%) traveled over an hour one way to their study visits. That's serious patient burden.
This issue is more than an inconvenience. It directly impacts recruitment, retention, and data integrity. Sponsors that prioritize strategies to reduce patient travel burden in clinical trials gain measurable advantages in enrollment velocity, participant satisfaction, and overall trial success.
Key Takeaways
- Travel burden slows enrollment and raises dropout: in CISCRP's 2025 survey, travel to the study clinic was the top source of participant disruption.
- Distance shapes who enrolls, since patients from more socially deprived areas are less likely to travel long distances for a trial.
- Six strategies cut travel: distributed assessment networks, mobile evaluation units, telemedicine, community outreach, travel support, and consolidated scheduling.
- 20/20 Onsite brings ophthalmic assessments to participants through Mobile Vision Clinics, Mobile Vision Pods, and Mobile Clinic Suites.
Why Travel Distance Matters More Than Convenience
Traditional site selection can often prioritize academic medical centers or large research hospitals. While these sites offer expertise, they are rarely located near where most patients reside. Long commutes introduce several challenges:
-
Socioeconomic exclusion: Working families face lost wages, childcare costs, and transportation expenses.
-
Rural underrepresentation: Remote and agricultural populations are often left out, skewing trial demographics.
-
Caregiver fatigue: Supporters must manage complex schedules and logistics, adding stress.
-
Cumulative burden: Repeated travel leads to fatigue, reduced adherence, and eventual dropout.
-
Emergency complications: When adverse events occur, patients living hours away cannot access care quickly.
Every additional mile represents increased risk of dropout, slower enrollment, and less diverse data.
6 Proven Strategies to Reduce Patient Travel Burden in Clinical Trials
Forward-thinking sponsors are overcoming these barriers by building proximity-based solutions into their protocols. Here are six strategies that have been shown to reduce patient travel burden in clinical trials by as much as 82%, from an average of 67 miles to 12 miles of travel.
1. Distributed Assessment Networks
Instead of funneling patients into centralized hubs, sponsors can deploy multi-hub networks across target regions. Partnering with local hospitals and community clinics ensures participants have access to trial services within a short driving distance, which is often less than 15 miles. Standardized protocols across all hubs ensure consistent data quality.
2. Mobile Evaluation Units
Mobile vision clinics bring specialized equipment and certified staff directly into patient communities. These units eliminate transportation barriers by delivering full ophthalmic or medical assessments in neighborhoods, workplaces, or schools. Routing strategies can be tailored to cover urban, suburban, and rural areas equitably.
3. Telemedicine Integration
Virtual assessments can replace unnecessary in-person visits, significantly reducing the number of required trips. Combined with digital health monitoring tools, telemedicine creates hybrid models where only essential visits require travel, reducing the overall patient burden while preserving protocol integrity.
4. Community Outreach Programs
Partnering with local providers ensures assessments can be performed close to home while maintaining quality through training and oversight. Community engagement also enhances trust and inclusivity, particularly among underrepresented populations, by addressing their cultural and linguistic needs.
5. Transportation and Lodging Support
For visits that cannot be eliminated, sponsors can coordinate professional transportation or provide travel stipends. Offering lodging near sites for long-distance participants further reduces dropout risk and improves patient satisfaction.
6. Optimized Visit Scheduling
Smart scheduling consolidates multiple assessments into fewer visits, offering flexible appointment times that fit participants’ daily lives. Real-time scheduling systems also allow patients to select time slots that minimize disruptions to work and family responsibilities.
Why Successful Trials Need Accessibility Support
Every successful trial requires a geographical strategy that extends far beyond institutional relationships and traditional site selection criteria.
|
Travel Challenge |
Traditional Sites |
Mobile Resolution |
|
Geographic Distance |
Participants travel 67+ miles on average |
82% travel reduction |
|
Transportation Costs |
Participants can bear travel and lodging expenses |
On-site evaluations eliminate transportation needs |
|
Time Investment |
Full-day commitments, including travel time |
Convenient local appointments within participant schedules |
|
Schedule Conflicts |
Rigid appointment timing despite travel complexities |
Flexible scheduling accommodating participant availability |
|
Accessibility Barriers |
Rural and underserved populations are often excluded |
Distributed networks ensure equitable access |
|
Retention Challenges |
Travel fatigue can cause progressive withdrawal |
Local convenience maintains sustained participation |
The Impact of Reducing Travel Burden
Implementing these strategies delivers measurable results. 20/20 Onsite has witnessed:
-
82% reduction in average travel distance: From 67 miles to just 12 miles.
-
95+ patient NPS score: Compared to the industry average NPS score of 30-50.
-
70% lower dropout rates: 9% in 20/20 Onsite-supported trials vs. 30% industry average.
Reducing patient travel burden in clinical trials is more than a logistical improvement. Reducing patient travel burden directly enhances trial performance, data quality, and inclusivity.
Why Accessibility Planning Protects Scientific Integrity
Travel challenges don’t just affect timelines. Travel challenges affect the science itself. When participants drop out or certain populations are underrepresented, data integrity suffers. Regulatory bodies expect diverse, representative populations, and accessibility is key to meeting these requirements.
20/20 Onsite specializes in integrating accessibility into trial design. 20/20 Onsite's Mobile Vision Clinics, Mobile Vision Pods, and Mobile Clinic Suites deliver ophthalmic assessments at the point of need, reducing patient burden while preserving rigorous endpoint protection.
Turning Distance Into an Advantage
Sponsors that fail to address travel challenges risk enrollment delays, budget overruns, and compromised data. Those who plan proactively gain an edge: faster recruitment, greater retention, and stronger outcomes.
20/20 Onsite helps sponsors reduce patient travel burden in clinical trials through mobile, modular, and integrated solutions. By bringing high-quality ophthalmic assessments directly to participants, 20/20 Onsite turns distance into a competitive advantage.
Ready to reduce patient travel burden in your next trial?
Request a travel reduction analysis to see how proximity strategies can accelerate your study.
Frequently Asked Questions
How Does Travel Burden Affect Clinical Trial Enrollment and Dropout Rates?
Travel burden slows enrollment and raises dropout, especially in trials with frequent site visits. In CISCRP's 2025 survey, travel to the study clinic was the top source of participant disruption, and 13% of those who left a study early cited the study center's location.
What Can Sponsors Do to Plan for Travel Burden?
Map where likely participants live before choosing sites. Then consolidate assessments into fewer visits, offer travel support, and bring specialized exams closer to participants. Our guide to why transportation is a timeline risk covers the planning in detail.
Does Travel Reimbursement Help Reduce Dropout?
It can help. In CISCRP's 2025 survey, 14% of participants who left a study early said reimbursement for out-of-pocket expenses would have kept them enrolled, yet 1 in 3 participants received no reimbursement at all.
Which Patient Retention Strategies Reduce Dropout in Clinical Trials?
Start by reducing the time and cost of participation: fewer site visits, flexible scheduling, travel support, and visits close to home. In CISCRP's 2025 survey, 76% of participants rated visits at or close to home as very helpful. See more ways to reduce patient dropout.
How Does 20/20 Onsite Reduce Travel for Ophthalmic Assessments?
20/20 Onsite brings ophthalmic assessments closer to participants through Mobile Vision Clinics, Mobile Vision Pods, and Mobile Clinic Suites. Trials it supports have averaged a 9% dropout rate, compared with an industry average of 30%. Talk to an Ophthalmic Trial Specialist to plan yours.